Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUNMY0)

• Drug Name: Ralfinamide Drug Info
• Synonyms: Ralfinamida; Ralfinamide [INN]; NW 1029; NW-1029; Ralfinamida [INN-Spanish]; (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide; (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide

Indication

Disease Entry	ICD 11	Status	REF
Neuropathic pain	8E43.0	Phase 3	[1]

• Therapeutic Class: Analgesics
• Cross-matching ID:
  PubChem CID: 5745207
  CAS Number: CAS 133865-88-0
  TTD Drug ID: DMUNMY0
  VARIDT Drug ID: DR01025

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[2]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[3]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[4]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[5]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[6]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[7]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[8]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[9]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[10]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[11]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[12]
Ziconotide	DMSLJP4	Pain	MG30-MG3Z	Approved	[13]
Hesperidin	DMI5DW1	Vascular purpura	3B60	Approved	[14]
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[15]
CNV-2197944	DMLT7JV	Pain	MG30-MG3Z	Phase 2	[16]
Ritanserin	DM0X36Y	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[17]
CNSB-004	DMHAI0M	Pain	MG30-MG3Z	Preclinical	[18]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[19]
PD-157667	DM61NFD	N. A.	N. A.	Terminated	[20]
PD-0204318	DMGKVPH	Pain	MG30-MG3Z	Terminated	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[1]
Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)	TT4FDG6	CAC1B_HUMAN	Blocker	[1]

References

• [1] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [2] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [3] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [4] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [5] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [6] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [7] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [8] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [11] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [12] Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
• [13] Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
• [14] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [15] N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
• [16] Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
• [17] N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
• [18] CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [20] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [21] US patent application no. 2012,0172,429, Permanently charged sodium and calcium channel blockers as anti- inflammatory agents.